Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA7 | P43166 | 3/20 | 0.44 |
| ▸ | CA9 | Q16790 | 3/20 | 0.44 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.36 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29367537 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL29396701 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL30517362 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL29359151 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL31593 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL30007746 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL1231880 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL10290527 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL29930052 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL42030 | 1.00 | CA1 (0.44) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180093943-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | Janssen Pharmaceuticals, Inc. (US) | 2018-04-05 | — | — | US | disclosed |
| US-20170173572-A1 | CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-06-22 | — | — | US | disclosed |
| EP-2531486-B1 | NOVEL PROCESS FOR THE PREPARATION OF NITROGEN SUBSTITUTED AMINOTETRALINS DERIVATIVES | UCB BIOPHARMA SPRL (BE) | 2017-06-21 | — | — | EP | disclosed |
| US-8785655-B2 | Ionic liquid solvents | DUBLIN CITY UNIVERSITY (IE) | 2014-07-22 | — | — | US | disclosed |
| US-8729306-B2 | Process for the preparation of nitrogen substituted aminotetralins derivatives | UCB PHARMA GMBH (DE) | 2014-05-20 | — | — | US | disclosed |
| US-20120302790-A1 | Novel Process for the Preparation of Nitrogen Substituted Aminotetralins Derivatives | UCB PHARMA, S.A. (BE) | 2012-11-29 | — | — | US | disclosed |
| WO-2012041986-A1 | PROCESS FOR THE PREPARATION OF AMINO ACID DERIVATIVES | UCB PHARMA GMBH (DE) | 2012-04-05 | — | — | WO | disclosed |
| US-20120071661-A1 | Ionic Liquid Solvents | DUBLIN CITY UNIVERSITY (IE) | 2012-03-22 | — | — | US | disclosed |
| US-7994335-B2 | Electronically tuned ligands for asymmetric hydrogenation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-09 | — | — | US | disclosed |
| EP-1477478-B1 | 2-oxo-1-pyrrolidine derivatives, process for preparing them and their uses. | UCB FARCHIM S A AG LTD (CH) | 2010-11-17 | — | — | EP | disclosed |
| US-6706926-B1 | ENANTIOSELECTIVE HYDROGENATION CATALYSTS | ISIS INNOVATION LIMITED (GB) | 2004-03-16 | — | — | US | disclosed |
| EP-1124833-B1 | DIPHOSPHINES | ISIS INNOVATION (GB) | 2003-01-08 | — | — | EP | disclosed |
| EP-1124833-A1 | DIPHOSPHINES | ISIS INNOVATION LIMITED (GB) | 2001-08-22 | — | — | EP | disclosed |
| WO-2000026220-A1 | DIPHOSPHINES | ISIS INNOVATION LIMITED (GB) | 2000-05-11 | — | — | WO | disclosed |
| US-4665087-A | ANGIOTENSIN-CONVERTING ENZYME INHIBITORS | CIBA-GEIGY CORPORATION (US) | 1987-05-12 | — | — | US | disclosed |
| US-4479963-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1984-10-30 | — | — | US | disclosed |
| EP-0105919-A1 | 1-CARBOXYALKANOYLPERHYDROINDOLE-2-CARBOXYLIC ACIDS AND DERIVATIVES. | CIBA GEIGY AG (CH) | 1984-04-25 | — | — | EP | disclosed |
| WO-1983003828-A1 | 1-CARBOXYALKANOYLPERHYDROINDOLE-2-CARBOXYLIC ACIDS AND DERIVATIVES | CIBA-GEIGY AG (CH) | 1983-11-10 | — | — | WO | disclosed |
| US-4390700-A | HYPOTENSIVE AGENTS, CARDIOVASCULAR DISORDERS | CIBA-GEIGY CORPORATION (US) | 1983-06-28 | — | — | US | disclosed |
| US-4374847-A | HYPOTENSIVE AGENTS | CIBA-GEIGY CORPORATION (US) | 1983-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170173572-A1 | CHIRAL LIGAND-BASED METAL-ORGANIC FRAMEWORKS FOR BROAD-SCOPE ASYMMETRIC CATALYSIS | POF1B, FGFR1, COASY | CA1 1158/4885CA2 1771/4885CA7 619/4885 |
| US-20120071661-A1 | Ionic Liquid Solvents | EBP, PAICS, HACD3 | CA1 483/4885CA2 114/4885CA7 199/4885 |
| US-20120302790-A1 | Novel Process for the Preparation of Nitrogen Substituted Aminotetralins Derivatives | AADAT, AANAT, ASNS | CA1 2554/4885CA2 2331/4885CA7 1537/4885 |
| US-20180093943-A1 | Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV | CTRC, HAVCR2, HGFAC | CA1 4407/4885CA2 4781/4885CA7 4560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.